Document is current
Any future updates will be listed below
-
Authors
Khan, Aliya A. https://orcid.org/0000-0003-3733-8956
AbuAlrob, Hajar
Ali, Dalal S.
Al Kassem, Zayd
Almoulia, Abdulrahman
Afifi, Habiba
Braga, Manoela
Cheng, Alice
Malhem, Jouma
Millar, Adam
Morgante, Emmett
Muhammad, Parwana
Paul, Terri L.
Prebtani, Ally
Punthakee, Zubin
Khan, Tayyab
Khan, Sarah
Shrayyef, Muhammad
Van Uum, Stan
Young, James Edward Massey
Brandi, Maria Luisa
Ovize, Michel
Weiss, Blandine
-
Funding
Funding for this research was provided by:
Amolyt Pharma
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 24 January 2025
First Online: 16 February 2025
Declarations
:
: The ethical approval for the present study was obtained from the Hamilton Integrated Research Ethics Board (Project No. 15196).
: Informed consent was obtained from all participants per GCP guidelines.
: Aliya A Khan: speaker and advisory board (Alexion, Amgen); speaker, advisory board, research funding (Ascendis); advisory board, research funding (Takeda); research funding (Amolyt, Calcilytix); Hajar Abu Alrob, Dalal S Ali, Abdulrahman Almoulia, Habiba Afifi, Manoela Braga, Alice Cheng, Jouma Malhem, Adam Millar, Emmett Morgante, Parwana Muhammad, Terri Paul, Ally Prebtani, Zubin Punthakee, Tayyab Khan, Sarah Khan, Fizsa Shah, Muhammad Shrayyef, Stan Van Uum, and James Edward Massey Young have no conflict of interest; Michel Ovize and Blandine Weiss are employees of Amolyt Pharma.
